Icon – Clinical Research Advancements & Q1 2023 Business Expectations

  • Credit
  • Healthcare
  • North America


Former EVP at Icon plc


  • Developments within the CRO (contract research organisation) space, highlighting clinical research advancements as it pertains to Icon (NASDAQ: ICLR)
  • Q3 2022 results and Q4 2022 performance expectations, discussing new business wins, net book-to-bill ratio and closing backlog
  • Breadth of clinical research services offered across various therapeutic areas – early-phase clinical development, decentralised and hybrid clinical trials and RWE (real-world evidence), among others
  • Icon’s competitive positioning relative to alternative CRO conglomerates post acquisition of PRA Health Sciences
  • 6-12-month company outlook, highlighting near-term technological and ancillary growth opportunities


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited